What does product — total collaboration revenue mean?

This metric represents the total revenue recognized from collaborative research, development, and licensing agreements specifically attributed to the company's product development segment. It reflects the financial value generated through partnerships where the company shares intellectual property or development responsibilities with other entities. Tracking this revenue stream is essential for evaluating the commercial success and market validation of the company's proprietary therapeutic pipeline.

Denali Therapeutics Inc. DNLI Product — Total collaboration revenue

Other product segments

Milestone Triggered

$25M—

Milestone Payment

$2.5M0.0%

Option Fee Payment

$2.5M+100%

Similar metrics at other companies

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

TVTXLicense and collaboration revenue — Total Revenue

$2.71M-54.1%

BCRXCollaborative and other revenues — Total revenues

$2M+14.3%

RCUSOther collaboration — Total revenues

$5M-37.5%

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

EXELCollaboration — Total revenues

$55.84M+32.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s product — total collaboration revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s product — total collaboration revenue?: Denali Therapeutics Inc. (DNLI) reported product — total collaboration revenue of $0 in Q4 2026.
What does product — total collaboration revenue mean?: This metric represents the total revenue recognized from collaborative research, development, and licensing agreements specifically attributed to the company's product development segment. It reflects the financial value generated through partnerships where the company shares intellectual property or development responsibilities with other entities. Tracking this revenue stream is essential for evaluating the commercial success and market validation of the company's proprietary therapeutic pipeline.